168 related articles for article (PubMed ID: 11742700)
41. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
42. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
43. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Gandara DR; Vokes E; Green M; Bonomi P; Devore R; Comis R; Carbone D; Karp D; Belani C
J Clin Oncol; 2000 Jan; 18(1):131-5. PubMed ID: 10623703
[TBL] [Abstract][Full Text] [Related]
44. [Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer].
Kudo S; Hino M; Fujita A; Igarashi T; Arita K; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1994 Nov; 21(15):2617-23. PubMed ID: 7979422
[TBL] [Abstract][Full Text] [Related]
45. Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study.
De Petris L; Migliorino MR; Ceribelli A; Martelli O; Di Molfetta M; Mancuso A; De Santis S; Di Salvia R; De Marinis F
Anticancer Res; 2005; 25(6C):4713-7. PubMed ID: 16334165
[TBL] [Abstract][Full Text] [Related]
46. Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
Mukohara T; Takeda K; Miyazaki M; Takifuji N; Terakawa K; Negoro S
Cancer Chemother Pharmacol; 2001 Nov; 48(5):356-60. PubMed ID: 11761452
[TBL] [Abstract][Full Text] [Related]
47. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
48. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
[TBL] [Abstract][Full Text] [Related]
49. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
[TBL] [Abstract][Full Text] [Related]
50. A phase II trial of docetaxel in advanced non-small cell lung cancer.
Saarinen A; Jekunen A; Halme M; Pyrhönen S; Tamminen K; Boyer R; Roubille N; Mattson K
Anticancer Drugs; 1996 Nov; 7(8):890-2. PubMed ID: 8991195
[TBL] [Abstract][Full Text] [Related]
51. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
52. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Wu HG; Bang YJ; Choi EK; Ahn YC; Kim YW; Lim TH; Suh C; Park K; Park CI
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):75-80. PubMed ID: 11777624
[TBL] [Abstract][Full Text] [Related]
55. Docetaxel (Taxotere) administered in weekly schedules.
Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
[TBL] [Abstract][Full Text] [Related]
56. Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Mattson K
Ann Oncol; 1999; 10 Suppl 5():S69-72. PubMed ID: 10582143
[TBL] [Abstract][Full Text] [Related]
57. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.
Serke M; Schoenfeld N; Loddenkemper R
Anticancer Res; 2004; 24(2C):1211-6. PubMed ID: 15154649
[TBL] [Abstract][Full Text] [Related]
58. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up.
Brunsvig PF; Hatlevoll R; Berg R; Lauvvang G; Owre K; Wang M; Aamdal S
Lung Cancer; 2005 Oct; 50(1):97-105. PubMed ID: 16005105
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Mattson KV; Abratt RP; ten Velde G; Krofta K
Ann Oncol; 2003 Jan; 14(1):116-22. PubMed ID: 12488303
[TBL] [Abstract][Full Text] [Related]
60. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
